We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+20.65%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$330M
AUM Growth
+$6.54M
Cap. Flow
+$8.01M
Cap. Flow %
2.43%
Top 10 Hldgs %
38.17%
Holding
104
New
22
Increased
33
Reduced
18
Closed
24

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$17.8M
2
URGN icon
UroGen Pharma
URGN
+$8.17M
3
MRSN
Mersana Therapeutics
MRSN
+$7.61M
4
GOSS icon
Gossamer Bio
GOSS
+$7.06M
5
CBAY
Cymabay Therapeutics
CBAY
+$5.7M

Top Sells

Rank Stock Value
1
SDGR icon
Schrodinger
SDGR
+$10.3M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$10.2M
3
AKRO
Akero Therapeutics
AKRO
+$9.78M
4
KRYS icon
Krystal Biotech
KRYS
+$5.78M
5
ETNB
89bio
ETNB
+$5.64M

Sector Composition

Rank Sector Weight
1 Healthcare 81.31%
2 Miscellaneous 18.62%
3 Consumer Staples 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$21.9M 6.64%
+300,000
New +$24M
IMGN
2
DELISTED
Immunogen Inc
IMGN
$20.7M 6.29%
1,307,435
-112,565
-8% -$1.87M
MORF
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$13.5M 4.1%
590,829
+338,520
+134% +$17.8M
MRUS
4
DELISTED
Merus
MRUS
$11.8M 3.57%
500,000
-89,255
-15% -$2.16M
SLNO
5
DELISTED
Soleno Therapeutics
SLNO
$10.9M 3.31%
+370,000
New +$2.24M
ITCI
6
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$10.9M 3.3%
208,730
+10,007
+5% +$583K
AKRO
7
CALL
DELISTED
Akero Therapeutics
AKRO
$10.1M 3.07%
200,000
-36,500
-15% -$1.7M
CBAY
8
DELISTED
Cymabay Therapeutics
CBAY
$8.8M 2.67%
590,000
+430,000
+269% +$5.7M
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$8.71M 2.64%
200,000
+108,787
+119% +$3.88M
PSTX
10
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$8.49M 2.57%
3,567,985
+622,037
+21% +$1.3M
KRYS icon
11
Krystal Biotech
KRYS
$10.4B
$8.3M 2.52%
71,531
-47,410
-40% -$5.78M
BIIB icon
12
Biogen
BIIB
$32.3B
$7.21M 2.19%
28,069
+1,215
+5% +$325K
URGN icon
13
UroGen Pharma
URGN
$2.13B
$7.13M 2.16%
+508,883
New +$8.17M
UTHR icon
14
United Therapeutics
UTHR
$22.1B
$7.1M 2.15%
31,424
+1,395
+5% +$321K
PRAX icon
15
Praxis Precision Medicines
PRAX
$9.63B
$7.04M 2.14%
274,528
+42,784
+18% +$809K
ORIC icon
16
Oric Pharmaceuticals
ORIC
$1.37B
$6.8M 2.06%
1,123,345
-327,477
-23% -$2.68M
CRNX icon
17
Crinetics Pharmaceuticals
CRNX
$9B
$6.54M 1.98%
+220,000
New +$4.53M
MRTX
18
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$6.53M 1.98%
150,000
– –
COGT icon
19
Cogent Biosciences
COGT
$6.02B
$6.35M 1.93%
651,372
+31,372
+5% +$372K
MRSN
20
DELISTED
Mersana Therapeutics
MRSN
$6.35M 1.93%
200,000
+160,000
+400% +$7.61M
RYTM icon
21
Rhythm Pharmaceuticals
RYTM
$7.38B
$5.97M 1.81%
260,537
+144,369
+124% +$3.23M
MGNX icon
22
MacroGenics
MGNX
$263M
$5.89M 1.79%
1,264,158
+48,483
+4% +$241K
BCRX icon
23
BioCryst Pharmaceuticals
BCRX
$2.51B
$5.61M 1.7%
791,671
+30,767
+4% +$221K
NVO
24
Novo Nordisk
NVO
$202B
$5.46M 1.65%
+60,000
New +$5.29M
AKRO
25
PUT
DELISTED
Akero Therapeutics
AKRO
$5.39M 1.63%
+106,600
New +$4.96M
1
2 3 4 5

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Silverarc Capital Management held 104 positions worth $330M, up 2% from $323M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Silverarc Capital Management's Q3 2023 filing shows 22 new, 33 increased, 18 reduced and 24 closed positions. Its largest new stake was UroGen Pharma: 508,883 shares worth $7.13M. The largest sale was Schrodinger, an estimated $10.3M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 92% a quarter earlier, followed by Miscellaneous and Consumer Staples.

  • Silverarc Capital Management's largest Q3 2023 buy was UroGen Pharma: 508,883 shares worth $7.13M.
  • Silverarc Capital Management added most to Morphic Holding, Inc. Common Stock in Q3 2023, an estimated $17.8M increase.
  • Silverarc Capital Management's biggest Q3 2023 reduction was Schrodinger, cutting an estimated $10.3M.
  • Silverarc Capital Management fully exited MoonLake Immunotherapeutics in Q3 2023, selling an estimated $10.2M.
  • Silverarc Capital Management's ten largest holdings make up 38% of its $330M portfolio in Q3 2023.
  • Silverarc Capital Management opened 22 new positions and closed 24 in Q3 2023.
  • Silverarc Capital Management's portfolio value rose 2% quarter-over-quarter to $330M.

Based on Silverarc Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.